



May 2026 Grand Rounds: Artificial Intelligence & the Changing Landscape of Obesity Medicine

Credit for this course may not exceed 1 credit when both the live and enduring material activity format credits are combined.

Live Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

On-Demand Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Important Dates for On-Demand Course (Enduring Material)

Date of Release: June 15, 2026

Date of Termination: December 31, 2028

Learning Objectives

At the conclusion of this activity, participants should be able to:

1. Describe key concepts of AI and its applications in obesity medicine, including disease phenotyping and prediction of treatment response.
2. Evaluate AI-enabled tools and digital health technologies for their clinical validity, utility, and limitations in obesity care.
3. Apply AI-driven insights and digital technologies in clinical practice to support personalized, longitudinal obesity management while considering ethical and equity implications.

Commercial Support

No commercial support was received for this activity.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities¹ (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed. In the list below, the nature of the relationship and company are followed by the industry of that company.

Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker).

Panelists and Speakers:

¹ An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below. All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that “The content and/or presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased.”

Speaker Disclosures:

Gitanjali Srivastava, MD	Corporate Advisory Board relationship with Lilly, NovoNordisk (Pharmaceuticals) Speakers Bureau relationship with Rhythm (Pharmaceuticals) Advisor relationship with Boehringer Ingelheim, Madrigal (pharmaceuticals), Quest Diagnostics (Biomedical) Researcher relationship with Recordati, Eli Lilly (Pharmaceuticals)
--------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Planner Disclosures:

Sriram Machenini, MD	Advisor relationship with Abbie Inc. (Pharmaceuticals), Eli Lilly (Pharmaceuticals) and NeurogastriX (Pharmaceuticals) Consultant relationship with Rhythm (Pharmaceuticals)
Angela Golden, DNP	Advisor relationship with Acella (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Currax (Pharmaceuticals), Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). Speaker relationship with Acella (Pharmaceuticals), Currax (Pharmaceuticals), Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals)

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

Bibliography

- Huang L, Huhulea EN, Abraham E, Bienenstock R, Aifuwa E, Hirani R, Schulhof A, Tiwari RK, Etienne M. The Role of Artificial Intelligence in Obesity Risk Prediction and Management: Approaches, Insights, and Recommendations. *Medicina (Kaunas)*. 2025 Feb 19;61(2):358. doi: 10.3390/medicina61020358. PMID: 40005474; PMCID: PMC11857386.
- Azmi S, Kunnathodi F, Alotaibi HF, Alhazzani W, Mustafa M, Ahmad I, Anvarbatcha R, Lytras MD, Arafat AA. Harnessing Artificial Intelligence in Obesity Research and Management: A Comprehensive Review. *Diagnostics (Basel)*. 2025 Feb 6;15(3):396. doi: 10.3390/diagnostics15030396. PMID: 39941325; PMCID: PMC11816645.
- Kim DW, Park CY, Shin JH, Lee HJ. The Role of Artificial Intelligence in Obesity Medicine. *Endocrinol Metab Clin North Am*. 2025 Mar;54(1):207-215. doi: 10.1016/j.ecl.2024.10.008. Epub 2024 Nov 12. PMID: 39919876.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated May 6, 2026